• Skip to content
  • Skip to navigation
  • Skip to footer
AstraZeneca logo AstraZeneca logo
AstraZeneca logo AstraZeneca logo
  • What science can do
    What science can do
    • Stories of impact
    • Publications
  • R&D
    R&D
    • Our approach
      Our approach to R&D
      • Oncology R&D strategy
      • Rare Disease R&D Strategy
      • STEM at AstraZeneca
    • Innovation in medicines
      Innovation in medicines overview
      • Cell therapies
      • Oligonucleotide therapeutics
    • Science & Technologies
      Science & Technologies overview
      • AI and data
      • Genomics
    • Patient Commitment
    • R&D Collaborations
    • Our R&D centres
    Featured website AstraZeneca Clinical Trials Clinical trial website thumbnail Featured website Open Innovation OpenInnovation logo
  • Our therapy areas
    Our therapy areas
    • Oncology
    • BioPharmaceuticals
    • Cardiovascular, Renal and Metabolism
    • Respiratory & Immunology
    • Infectious Disease
    • Rare Disease
    • Pipeline
    • All medicines
  • Our company
    Our company
    • Our history
    • Our leadership
    • Cambridge
    • Gothenburg
    • Gaithersburg
  • Careers
    Careers
    • Great place to work
    • Inclusion and diversity
    • Learning and development
    • Employee resource groups
  • Investors
    Investor Relations (Global)
    • Investor Relations (Sweden)
    • Resources
    • Governance
    • Shareholder information
    • Dividend policy
    • Key facts
    • FAQs
    • Debt Investors
    • Investor Relations contacts
    • Annual Report 2025
    Feature Results and presentations ipad image
  • Media
    Media
    • Press Releases
    • Articles
    • Image library
    • Archive
    • Media contacts
  • Sustainability
    Sustainability
    • Climate change
      Climate change overview
      • Renewables
      • Product sustainability
      • Electric vehicles and Sustainable transport
    • Nature
      Nature overview
      • Water stewardship
      • Pharmaceuticals in the environment
      • Waste and circularity
      • AZ Forest
    • Health equity
      Health equity overview
      • Science
      • Healthcare delivery
      • Community investment
    • Health systems resilience
      Health systems resilience overview
      • Partnership for Health System Sustainability and Resilience (PHSSR)
    • Ethics and governance
      Ethics and Compliance
      • Governance
      • Sustainability governance
    • Our people
      Great place to work
      • Inclusion and diversity
      • Learning and development
      • Workforce safety and health
    • Our Values
    • Partnerships and alliances
    • Resources
      Sustainability resources
      • Our sustainability impact
    Feature Our Sustainability Impact Feature Sustainable science
  • Partnering
    Partnering
    • Our business development teams
    • Our areas of partnering interest
    • Why partner with AstraZeneca?
    • Information for Suppliers
    • Supplier Sustainability Hub
    • Sustainable procurement
    • A Catalyst Network
  • AstraZeneca Websites
  • Global site

Results 1 – 10 of 151 for vaccine Covid (0.04 seconds)

AstraZeneca’s and mRNA vaccines provide equivalent protection against COVID-19 hospitalisation and deaths

AstraZeneca’s and mRNA vaccines provide equivalent protection against COVID-19 hospitalisation and deaths

27 April 2022

UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is effective and generally well-tolerated

UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is effective and generally well-tolerated

18 March 2021

COVID-19 Vaccine AstraZeneca highly effective at preventing COVID-19 severe outcomes and death when used as first or second booster, according to new real-world evidence study in Thailand

COVID-19 Vaccine AstraZeneca highly effective at preventing COVID-19 severe outcomes and death when used as first or second booster, according to new ...

13 December 2022

Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world less than 12 months after first approval

Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world less than 12 months after first approval

16 November 2021

AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand in August

AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand in August

3 September 2021

AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization

AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization

15 February 2021

COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant

COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant

15 June 2021

Update on the safety of COVID-19 Vaccine AstraZeneca

Update on the safety of COVID-19 Vaccine AstraZeneca

14 March 2021

Serum Institute of India obtains emergency use authorisation in India for AstraZeneca’s COVID-19 vaccine

Serum Institute of India obtains emergency use authorisation in India for AstraZeneca’s COVID-19 vaccine

6 January 2021

AstraZeneca’s COVID-19 vaccines made by Siam Bioscience pass quality testing in Europe and U.S., first batch delivery is near

AstraZeneca’s COVID-19 vaccines made by Siam Bioscience pass quality testing in Europe and U.S., first batch delivery is near

9 May 2021

Previous 1 2 3 4 5 6 7 8 9 10 Next

AstraZeneca Websites

This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.


Veeva ID: Z4-68564
Date of next review: August 2026

Resources

  • All resources
  • Open Innovation
  • Externally sponsored scientific research
  • Medical Information for HCPs
  • US prescription assistance programmes
  • Global clinical trials information
  • Medicines
  • Report a possible side effect

Quick links

  • Media
  • Investor Relations
  • Partnering
  • Careers
  • Sustainability
  • Modern Slavery Statement
  • AZethics – Report A Concern
  • Supplier information
  • Social Media Community Guidelines

Social Media

  • Linkedn
  • Instagram
  • Facebook
  • Twitter
  • YouTube
  • Glassdoor

utility links

  • Legal notice and Terms of Use
  • Privacy notice
  • Site map
  • Contact us
  • Cookie preferences

© AstraZeneca 2026

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.

I disagree I agree